Bausch Drug Patent Portfolio
Bausch owns 32 orange book drugs protected by 109 US patents with Cardizem Cd having the least patent protection, holding only 1 patent. And Jublia with maximum patent protection, holding 18 patents. Given below is the list of Bausch's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11389467 | Topical compositions | 28 Dec, 2040 | Active |
| US11311482 | Topical compositions and methods for treating skin diseases | 11 May, 2038 | Active |
| US11679116 | Topical compositions and methods for treating psoriasis | 06 Jun, 2036 | Active |
| US10251895 | Topical compositions and methods for treating psoriasis | 06 Jun, 2036 | Active |
| US10426787 | Topical compositions and methods for treating psoriasis | 06 Jun, 2036 | Active |
| US11648256 | Topical compositions and methods for treating psoriasis | 06 Jun, 2036 | Active |
| US11679115 | Topical compositions and methods for treating psoriasis | 06 Jun, 2036 | Active |
| US10478601 | Applicator | 25 Apr, 2035 | Active |
| US10342875 | Stabilized efinaconazole compositions | 02 Oct, 2034 | Active |
| US10828293 | Anti-infective methods, compositions, and devices | 02 Oct, 2034 | Active |
| US10864274 | Stabilized efinaconazole formulations | 02 Oct, 2034 | Active |
| US11654139 | Anti-infective methods, compositions, and devices | 02 Oct, 2034 | Active |
| US9662394 | Stabilized efinaconazole compositions | 02 Oct, 2034 | Active |
| US8980931 | Method of evaluating pharmaceutical preparation containing luliconazole and index substance | 28 Apr, 2034 | Active |
| US9012484 | Crystal and pharmaceutical preparation containing the same crystal | 06 Sep, 2033 | Active |
| US9199977 | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal | 06 Sep, 2033 | Active |
| US9453006 | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | 06 Sep, 2033 | Active |
| US9192615 | Method for the treatment of acne and certain dosage forms thereof | 17 Nov, 2031 | Active |
| US10478502 | Pharmaceutical formulations containing corticosteroids for topical administration | 02 Nov, 2031 | Active |
| US11839656 | Pharmaceutical formulations containing corticosteroids for topical administration | 02 Nov, 2031 | Active |
| US11957753 | Pharmaceutical formulations containing corticosteroids for topical administration | 02 Nov, 2031 | Active |
| US11986527 | Pharmaceutical formulations containing corticosteroids for topical administration | 02 Nov, 2031 | Active |
| US12076403 | Pharmaceutical formulations containing corticosteroids for topical administration | 02 Nov, 2031 | Active |
| US8809307 | Pharmaceutical formulations containing corticosteroids for topical administration | 02 Nov, 2031 | Active |
| US8486978 | Compositions and methods for treating diseases of the nail | 24 Oct, 2030 | Active |
| US9302009 | Compositions and methods for treating diseases of the nail | 24 Oct, 2030 | Active |
| US10105444 | Compositions and methods for treating diseases of the nail | 08 Jul, 2030 | Active |
| US8039494 | Compositions and methods for treating diseases of the nail | 08 Jul, 2030 | Active |
| US9861698 | Compositions and methods for treating diseases of the nail | 08 Jul, 2030 | Active |
| US10918635 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | 30 Apr, 2030 | Active |
| US11202752 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy | 30 Apr, 2030 | Active |
| US11850245 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | 30 Apr, 2030 | Active |
| US10238644 | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | 11 Dec, 2029 | Active |
| US11318130 | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | 11 Dec, 2029 | Active |
| US8222270 | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod | 11 Dec, 2029 | Active |
| US8236816 | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod | 11 Dec, 2029 | Active |
| US8299109 | Method of treating actinic keratosis with 3.75% imiquimod cream | 11 Dec, 2029 | Active |
| US10238645 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | 18 Aug, 2029 | Active |
| US8598196 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy | 18 Aug, 2029 | Active |
| US8288434 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 05 Aug, 2029 | Active |
| US10220049 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US10624918 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US8663699 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US8895070 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US9078870 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US9561208 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US10137142 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US9504704 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent | 03 Jun, 2029 | Active |
| US10512640 | Compositions and methods for treating diseases of the nail | 03 Jan, 2028 | Active |
| US10828369 | Compositions and methods for treating diseases of the nail | 03 Jan, 2028 | Active |
| US11213519 | Compositions and methods for treating diseases of the nail | 03 Jan, 2028 | Active |
| US11872218 | Compositions and methods for treating diseases of the nail | 03 Jan, 2028 | Active |
| US9566272 | Compositions and methods for treating diseases of the nail | 03 Jan, 2028 | Active |
| US9877955 | Compositions and methods for treating diseases of the nail | 03 Jan, 2028 | Active |
| US7541347 | Minocycline oral dosage forms for the treatment of acne | 02 Apr, 2027 | Active |
| US7544373 | Minocycline oral dosage forms for the treatment of acne | 02 Apr, 2027 | Active |
| US7919483 | Method for the treatment of acne | 07 Mar, 2027 | Active |
| US7378405 | Stabilized steroid composition and method for its preparation | 19 Dec, 2026 | Active |
| US7241805 | Modified release formulations of a bupropion salt | 27 Jun, 2026 | Active |
| US7569610 | Modified release formulations of a bupropion salt | 27 Jun, 2026 | Active |
| US7572935 | Modified release formulations of a bupropion salt | 27 Jun, 2026 | Active |
| US7585897 | Modified release formulations of a bupropion salt | 27 Jun, 2026 | Active |
| US7645802 | Bupropion hydrobromide and therapeutic applications | 27 Jun, 2026 | Active |
| US7649019 | Modified release formulations of a bupropion salt | 27 Jun, 2026 | Active |
| US7662407 | Modified release formulations of a bupropion salt | 27 Jun, 2026 | Active |
| US7671094 | Bupropion hydrobromide and therapeutic applications | 27 Jun, 2026 | Active |
| US7214506 | Method for treating onychomycosis | 22 Feb, 2026 | Active |
| US7790705 | Minocycline oral dosage forms for the treatment of acne | 24 Jun, 2025 | Active |
| US8252776 | Minocycline oral dosage forms for the treatment of acne | 24 Jun, 2025 | Active |
| US8268804 | Minocycline oral dosage forms for the treatment of acne | 24 Jun, 2025 | Active |
| US8722650 | Extended-release minocycline dosage forms | 24 Jun, 2025 | Active |
| US7981877 | Stabilized steroid composition and method for its preparation | 23 Jan, 2025 | Active |
| US7696159 | Treatment for basal cell carcinoma | 01 Oct, 2024 | Expired |
| US7696159 | Treatment for basal cell carcinoma | 01 Apr, 2024 | Expired |
| US8232264 | Compositions and methods for enhancing corticosteroid delivery | 09 Mar, 2023 | Expired |
| US7220424 | Compositions and methods for enhancing corticosteroid delivery | 07 Jan, 2023 | Expired |
| US7794738 | Compositions and methods for enhancing corticosteroid delivery | 11 Sep, 2022 | Expired |
| US6765001 | Compositions and methods for enhancing corticosteroid delivery | 21 Dec, 2021 | Expired |
| US7223387 | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester | 28 Feb, 2021 | Expired |
| US6923984 | Cushioning wax beads for making solid shaped articles | 25 Feb, 2021 | Expired |
| US6517847 | Topical gel delivery system | 03 Aug, 2020 | Expired |
| US6387383 | Topical low-viscosity gel composition | 03 Aug, 2020 | Expired |
| US5900488 | Method for treating mycosis using imidazolylacetonitrile derivatives | 18 Jan, 2020 | Expired |
| US7108866 | Chronotherapeutic diltiazem formulations and the administration thereof | 17 Dec, 2019 | Expired |
| US6423722 | Crystalline macrolides and process for their preparation | 26 Dec, 2018 | Expired |
| US6096341 | Delayed release tablet of bupropion hydrochloride | 30 Oct, 2018 | Expired |
| US6423722 | Crystalline macrolides and process for their preparation | 26 Jun, 2018 | Expired |
| US5908838 | Method for the treatment of acne | 19 Feb, 2018 | Expired |
| US6150337 | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes | 21 Nov, 2017 | Expired |
| US7981909 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | 16 Sep, 2017 | Expired |
| US8227490 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | 16 Sep, 2017 | Expired |
| US6514980 | Nucleoside analogs in combination therapy of herpes simplex infections | 24 Jan, 2017 | Expired |
| US5912238 | Heteroatoms-containing tricyclic compounds | 15 Dec, 2016 | Expired |
| US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | 05 Oct, 2016 | Expired |
| US5955109 | Methods and compositions for topical delivery of retinoic acid | 21 Sep, 2016 | Expired |
| US5912238 | Heteroatoms-containing tricyclic compounds | 15 Jun, 2016 | Expired |
| US6352998 | Pharmaceutical compositions | 26 Apr, 2016 | Expired |
| US6423342 | Process for the preparation of a solid pharmaceutical dosage form | 01 Mar, 2016 | Expired |
| USRE39264 | Pharmaceutical combination | 02 Feb, 2016 | Expired |
| US6352998 | Pharmaceutical compositions | 26 Oct, 2015 | Expired |
| US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | 14 Jul, 2015 | Expired |
| US5733886 | Compositions of clindamycin and benzoyl peroxide for acne treatment | 31 Mar, 2015 | Expired |
| USRE41134 | Slow release vehicles for minimizing skin irritancy of topical compositions | 24 Feb, 2015 | Expired |
| US5648093 | Pharmaceutical and other dosage forms | 15 Jul, 2014 | Expired |
| US5462740 | Rectally-administered, epileptic-seizure-inhibiting composition | 17 Sep, 2013 | Expired |
| US5536743 | Intravaginal treatment of vaginal infections with buffered metronidazole compositions | 16 Jul, 2013 | Expired |
| US5529791 | Extended release form of diltiazem | 25 Jun, 2013 | Expired |
| US5476875 | Catechol derivatives | 19 Dec, 2012 | Expired |
| US5439689 | Diltiazem formulation | 08 Aug, 2012 | Expired |
Latest Legal Activities on Bausch's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bausch.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 May, 2024 | US10864274 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Apr, 2024 | US10828293 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9504704 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8299109 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288434 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288434 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8288434 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Mar, 2024 | US8232264 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Feb, 2024 | US9453006 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Feb, 2024 | US8268804 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8236816 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8252776 (Litigated) |
| Recordation of Patent eGrant | 16 Jan, 2024 | US11872218 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Jan, 2024 | US11872218 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Jan, 2024 | US11872218 |
Bausch's Drug Patent Litigations
Bausch's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 26, 1995, against patent number US5955109. The petitioner , challenged the validity of this patent, with WON et al as the respondent. Click below to track the latest information on how companies are challenging Bausch's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11311482 | June, 2023 |
Institution Denied
(12 Jan, 2024)
| Bausch Health Ireland Limited et al. | Padagis Israel Pharmaceuticals Ltd. et al. |
| US7214506 | November, 2016 |
FWD Entered
(06 Jun, 2018)
| Kaken Pharmaceutical Co., Ltd. | Acrux DDS Pty Ltd. |
| US7214506 | May, 2017 |
Terminated-Settled
(13 Nov, 2017)
| Kaken Pharmaceutical Co., Ltd. et al. | Argentum Pharmaceuticals LLC et al. |
| US5912238 | November, 1997 |
Decision
(19 Nov, 1997)
| DONALD | |
| US5955109 | September, 1995 |
Decision
(18 Sep, 1997)
| WON et al | |
Bausch's Family Patents
Bausch Drug List
Given below is the complete list of Bausch's drugs and the patents protecting them.
1. Acanya
Acanya is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8288434 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
05 Aug, 2029
(4 years from now)
| Active |
| US10220049 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US10624918 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US8663699 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US8895070 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US9078870 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US5733886 | Compositions of clindamycin and benzoyl peroxide for acne treatment |
31 Mar, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acanya's drug page
2. Aldara
Aldara is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7696159
(Pediatric)
| Treatment for basal cell carcinoma |
01 Oct, 2024
(2 months ago)
| Expired |
| US7696159 | Treatment for basal cell carcinoma |
01 Apr, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aldara's drug page
3. Aplenzin
Aplenzin is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7241805 | Modified release formulations of a bupropion salt |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7569610 | Modified release formulations of a bupropion salt |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7572935 | Modified release formulations of a bupropion salt |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7585897 | Modified release formulations of a bupropion salt |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7645802 | Bupropion hydrobromide and therapeutic applications |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7649019 | Modified release formulations of a bupropion salt |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7662407 | Modified release formulations of a bupropion salt |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
| US7671094 | Bupropion hydrobromide and therapeutic applications |
27 Jun, 2026
(1 year, 6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aplenzin's drug page
4. Arazlo
Arazlo is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11311482 | Topical compositions and methods for treating skin diseases |
11 May, 2038
(13 years from now)
| Active |
| US11679116 | Topical compositions and methods for treating psoriasis |
06 Jun, 2036
(11 years from now)
| Active |
| US6517847 | Topical gel delivery system |
03 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arazlo's drug page
5. Bryhali
Bryhali is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10478502 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US11839656 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US11957753 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US11986527 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US12076403 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US8809307 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US6517847 | Topical gel delivery system |
03 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bryhali's drug page
Explore Our Curated Drug Screens
6. Cabtreo
Cabtreo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11389467 | Topical compositions |
28 Dec, 2040
(16 years from now)
| Active |
| US8288434 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
05 Aug, 2029
(4 years from now)
| Active |
| US10220049 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US10624918 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US9561208 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cabtreo's drug page
7. Cardizem Cd
Cardizem Cd is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5439689 | Diltiazem formulation |
08 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardizem Cd's drug page
8. Cardizem La
Cardizem La is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6923984 | Cushioning wax beads for making solid shaped articles |
25 Feb, 2021
(3 years ago)
| Expired |
| US7108866 | Chronotherapeutic diltiazem formulations and the administration thereof |
17 Dec, 2019
(5 years ago)
| Expired |
| US5529791 | Extended release form of diltiazem |
25 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardizem La's drug page
9. Clindagel
Clindagel is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6387383 | Topical low-viscosity gel composition |
03 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clindagel's drug page
10. Diastat
Diastat is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5462740 | Rectally-administered, epileptic-seizure-inhibiting composition |
17 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diastat's drug page
11. Diastat Acudial
Diastat Acudial is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5462740 | Rectally-administered, epileptic-seizure-inhibiting composition |
17 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diastat Acudial's drug page
12. Duobrii
Duobrii is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10251895 | Topical compositions and methods for treating psoriasis |
06 Jun, 2036
(11 years from now)
| Active |
| US10426787 | Topical compositions and methods for treating psoriasis |
06 Jun, 2036
(11 years from now)
| Active |
| US11648256 | Topical compositions and methods for treating psoriasis |
06 Jun, 2036
(11 years from now)
| Active |
| US11679115 | Topical compositions and methods for treating psoriasis |
06 Jun, 2036
(11 years from now)
| Active |
| US10478502 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US11839656 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US11957753 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US11986527 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US12076403 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US8809307 | Pharmaceutical formulations containing corticosteroids for topical administration |
02 Nov, 2031
(6 years from now)
| Active |
| US6517847 | Topical gel delivery system |
03 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duobrii's drug page
13. Elidel
Elidel is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6423722
(Pediatric)
| Crystalline macrolides and process for their preparation |
26 Dec, 2018
(5 years ago)
| Expired |
| US6423722 | Crystalline macrolides and process for their preparation |
26 Jun, 2018
(6 years ago)
| Expired |
| US5912238
(Pediatric)
| Heteroatoms-containing tricyclic compounds |
15 Dec, 2016
(8 years ago)
| Expired |
| US5912238 | Heteroatoms-containing tricyclic compounds |
15 Jun, 2016
(8 years ago)
| Expired |
| US6352998
(Pediatric)
| Pharmaceutical compositions |
26 Apr, 2016
(8 years ago)
| Expired |
| US6352998 | Pharmaceutical compositions |
26 Oct, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elidel's drug page
14. Jublia
Jublia is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10478601 | Applicator |
25 Apr, 2035
(10 years from now)
| Active |
| US10342875 | Stabilized efinaconazole compositions |
02 Oct, 2034
(9 years from now)
| Active |
| US10828293 | Anti-infective methods, compositions, and devices |
02 Oct, 2034
(9 years from now)
| Active |
| US10864274 | Stabilized efinaconazole formulations |
02 Oct, 2034
(9 years from now)
| Active |
| US11654139 | Anti-infective methods, compositions, and devices |
02 Oct, 2034
(9 years from now)
| Active |
| US9662394 | Stabilized efinaconazole compositions |
02 Oct, 2034
(9 years from now)
| Active |
| US8486978 | Compositions and methods for treating diseases of the nail |
24 Oct, 2030
(5 years from now)
| Active |
| US9302009 | Compositions and methods for treating diseases of the nail |
24 Oct, 2030
(5 years from now)
| Active |
| US10105444 | Compositions and methods for treating diseases of the nail |
08 Jul, 2030
(5 years from now)
| Active |
| US8039494 | Compositions and methods for treating diseases of the nail |
08 Jul, 2030
(5 years from now)
| Active |
| US9861698 | Compositions and methods for treating diseases of the nail |
08 Jul, 2030
(5 years from now)
| Active |
| US10512640 | Compositions and methods for treating diseases of the nail |
03 Jan, 2028
(3 years from now)
| Active |
| US10828369 | Compositions and methods for treating diseases of the nail |
03 Jan, 2028
(3 years from now)
| Active |
| US11213519 | Compositions and methods for treating diseases of the nail |
03 Jan, 2028
(3 years from now)
| Active |
| US11872218 | Compositions and methods for treating diseases of the nail |
03 Jan, 2028
(3 years from now)
| Active |
| US9566272 | Compositions and methods for treating diseases of the nail |
03 Jan, 2028
(3 years from now)
| Active |
| US9877955 | Compositions and methods for treating diseases of the nail |
03 Jan, 2028
(3 years from now)
| Active |
| US7214506 | Method for treating onychomycosis |
22 Feb, 2026
(1 year, 2 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jublia's drug page
15. Locoid
Locoid is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7378405 | Stabilized steroid composition and method for its preparation |
19 Dec, 2026
(1 year, 11 months from now)
| Active |
| US7981877 | Stabilized steroid composition and method for its preparation |
23 Jan, 2025
(a month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Locoid's drug page
16. Loprox
Loprox is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7981909 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
16 Sep, 2017
(7 years ago)
| Expired |
| US8227490 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
16 Sep, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Loprox's drug page
17. Luzu
Luzu is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8980931 | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
28 Apr, 2034
(9 years from now)
| Active |
| US9012484 | Crystal and pharmaceutical preparation containing the same crystal |
06 Sep, 2033
(8 years from now)
| Active |
| US9199977 | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
06 Sep, 2033
(8 years from now)
| Active |
| US9453006 | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
06 Sep, 2033
(8 years from now)
| Active |
| US5900488 | Method for treating mycosis using imidazolylacetonitrile derivatives |
18 Jan, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Luzu's drug page
18. Metrogel-vaginal
Metrogel-vaginal is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5536743 | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
16 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metrogel-vaginal's drug page
19. Onexton
Onexton is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8288434 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
05 Aug, 2029
(4 years from now)
| Active |
| US10137142 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US10220049 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US9504704 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US9561208 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
03 Jun, 2029
(4 years from now)
| Active |
| US5733886 | Compositions of clindamycin and benzoyl peroxide for acne treatment |
31 Mar, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onexton's drug page
20. Retin-a Micro
Retin-a Micro is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5955109 | Methods and compositions for topical delivery of retinoic acid |
21 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retin-a Micro's drug page
21. Retin-a-micro
Retin-a-micro is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5955109 | Methods and compositions for topical delivery of retinoic acid |
21 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Retin-a-micro's drug page
22. Solodyn
Solodyn is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9192615 | Method for the treatment of acne and certain dosage forms thereof |
17 Nov, 2031
(6 years from now)
| Active |
| US7541347 | Minocycline oral dosage forms for the treatment of acne |
02 Apr, 2027
(2 years from now)
| Active |
| US7544373 | Minocycline oral dosage forms for the treatment of acne |
02 Apr, 2027
(2 years from now)
| Active |
| US7919483 | Method for the treatment of acne |
07 Mar, 2027
(2 years from now)
| Active |
| US7790705 | Minocycline oral dosage forms for the treatment of acne |
24 Jun, 2025
(6 months from now)
| Active |
| US8252776 | Minocycline oral dosage forms for the treatment of acne |
24 Jun, 2025
(6 months from now)
| Active |
| US8268804 | Minocycline oral dosage forms for the treatment of acne |
24 Jun, 2025
(6 months from now)
| Active |
| US8722650 | Extended-release minocycline dosage forms |
24 Jun, 2025
(6 months from now)
| Active |
| US5908838 | Method for the treatment of acne |
19 Feb, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Solodyn's drug page
23. Targretin
Targretin is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
05 Oct, 2016
(8 years ago)
| Expired |
| US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
14 Jul, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Targretin's drug page
24. Tasmar
Tasmar is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5476875 | Catechol derivatives |
19 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tasmar's drug page
25. Tiazac
Tiazac is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5529791 | Extended release form of diltiazem |
25 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tiazac's drug page
26. Vanos
Vanos is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8232264 | Compositions and methods for enhancing corticosteroid delivery |
09 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US7220424 | Compositions and methods for enhancing corticosteroid delivery |
07 Jan, 2023
(1 year, 11 months ago)
| Expired |
| US7794738 | Compositions and methods for enhancing corticosteroid delivery |
11 Sep, 2022
(2 years ago)
| Expired |
| US6765001 | Compositions and methods for enhancing corticosteroid delivery |
21 Dec, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vanos's drug page
27. Virazole
Virazole is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6150337 | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
21 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Virazole's drug page
28. Wellbutrin Xl
Wellbutrin Xl is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6096341 | Delayed release tablet of bupropion hydrochloride |
30 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wellbutrin Xl's drug page
29. Xerese
Xerese is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7223387 | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
28 Feb, 2021
(3 years ago)
| Expired |
| US6514980 | Nucleoside analogs in combination therapy of herpes simplex infections |
24 Jan, 2017
(7 years ago)
| Expired |
| USRE39264 | Pharmaceutical combination |
02 Feb, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xerese's drug page
30. Zelapar
Zelapar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6423342 | Process for the preparation of a solid pharmaceutical dosage form |
01 Mar, 2016
(8 years ago)
| Expired |
| US5648093 | Pharmaceutical and other dosage forms |
15 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zelapar's drug page
31. Ziana
Ziana is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6387383 | Topical low-viscosity gel composition |
03 Aug, 2020
(4 years ago)
| Expired |
| USRE41134 | Slow release vehicles for minimizing skin irritancy of topical compositions |
24 Feb, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ziana's drug page
32. Zyclara
Zyclara is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10918635 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
30 Apr, 2030
(5 years from now)
| Active |
| US11202752 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
30 Apr, 2030
(5 years from now)
| Active |
| US11850245 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
30 Apr, 2030
(5 years from now)
| Active |
| US10238644 | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
11 Dec, 2029
(4 years from now)
| Active |
| US11318130 | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
11 Dec, 2029
(4 years from now)
| Active |
| US8222270 | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
11 Dec, 2029
(4 years from now)
| Active |
| US8236816 | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
11 Dec, 2029
(4 years from now)
| Active |
| US8299109 | Method of treating actinic keratosis with 3.75% imiquimod cream |
11 Dec, 2029
(4 years from now)
| Active |
| US10238645 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
18 Aug, 2029
(4 years from now)
| Active |
| US8598196 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
18 Aug, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyclara's drug page